File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Adefovir Dipivoxil Therapy for Lamivudine-Resistant Hepatitis B in Pre- and Post-Liver Transplantation Patients

TitleAdefovir Dipivoxil Therapy for Lamivudine-Resistant Hepatitis B in Pre- and Post-Liver Transplantation Patients
Authors
Issue Date2003
PublisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www.hepatology.org/
Citation
Hepatology, 2003, v. 38 n. 6, p. 1419-1427 How to Cite?
AbstractThree-+hundred and twenty-four patients were enrolled in an open-label, multicenter, international study in which pre- and post-liver transplantation (LT) patients with recurrent chronic hepatitis B (CHB) and evidence of lamivudine-resistant HBV were treated with adefovir dipivoxil 10 mg once daily. In the pre- and post-LT cohorts, 128 and 196 patients were treated for a median duration of 18.7 and 56.1 weeks, respectively. In patients who received 48 weeks of treatment, 81% of the pre-LT and 34% of the post-LT cohort achieved undetectable serum hepatitis B virus (HBV) DNA (Roche Amplicor Monitor™ polymerase chain reaction [PCR] assay lower limit of quantification [LLQ] < 400 copies/mL) with a median change in serum HBV DNA from baseline of -4.1 log10 and -4.3 log10 copies/mL, respectively. Serum alanine aminotransferase (ALT), albumin, bilirubin, and prothrombin time normalized in 76%, 81%, 50%, and 83% of pre-LT patients and 49%, 76%, 75%, and 20% of post-LT patients. The Child-Pugh-Turcotte (CPT) score improved in over 90% of patients in both cohorts. Genotypic analysis of 122 HBV baseline samples revealed that 98% of these patients had lamivudine-resistant mutant HBV. No adefovir resistance mutations were identified in patients after 48 weeks of therapy. One-year survival was 84% for pre-LT and 93% for post-LT patients (Kaplan-Meier analysis). Treatment-related adverse effects associated with adefovir dipivoxil in this setting were primarily mild to moderate in severity. In conclusion, 48 weeks of adefovir dipivoxil resulted in significant improvements in virologic, biochemical, and clinical parameters in CHB patients pre- and post-LT with lamivudine-resistant HBV.
Persistent Identifierhttp://hdl.handle.net/10722/77534
ISSN
2015 Impact Factor: 11.711
2015 SCImago Journal Rankings: 4.752
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorSchiff, ERen_HK
dc.contributor.authorLai, CLen_HK
dc.contributor.authorHadziyannis, Sen_HK
dc.contributor.authorNeuhaus, Pen_HK
dc.contributor.authorTerrault, Nen_HK
dc.contributor.authorColombo, Men_HK
dc.contributor.authorTillmann, HLen_HK
dc.contributor.authorSamuel, Den_HK
dc.contributor.authorZeuzem, Sen_HK
dc.contributor.authorLilly, Len_HK
dc.contributor.authorRendina, Men_HK
dc.contributor.authorVilleneuve, JPen_HK
dc.contributor.authorLama, Nen_HK
dc.contributor.authorJames, Cen_HK
dc.contributor.authorWulfsohn, MSen_HK
dc.contributor.authorNamini, Hen_HK
dc.contributor.authorWestland, Cen_HK
dc.contributor.authorXiong, Sen_HK
dc.contributor.authorChoy, GSen_HK
dc.contributor.authorVan Doren, Sen_HK
dc.contributor.authorFry, Jen_HK
dc.contributor.authorBrosgart, CLen_HK
dc.date.accessioned2010-09-06T07:32:57Z-
dc.date.available2010-09-06T07:32:57Z-
dc.date.issued2003en_HK
dc.identifier.citationHepatology, 2003, v. 38 n. 6, p. 1419-1427en_HK
dc.identifier.issn0270-9139en_HK
dc.identifier.urihttp://hdl.handle.net/10722/77534-
dc.description.abstractThree-+hundred and twenty-four patients were enrolled in an open-label, multicenter, international study in which pre- and post-liver transplantation (LT) patients with recurrent chronic hepatitis B (CHB) and evidence of lamivudine-resistant HBV were treated with adefovir dipivoxil 10 mg once daily. In the pre- and post-LT cohorts, 128 and 196 patients were treated for a median duration of 18.7 and 56.1 weeks, respectively. In patients who received 48 weeks of treatment, 81% of the pre-LT and 34% of the post-LT cohort achieved undetectable serum hepatitis B virus (HBV) DNA (Roche Amplicor Monitor™ polymerase chain reaction [PCR] assay lower limit of quantification [LLQ] < 400 copies/mL) with a median change in serum HBV DNA from baseline of -4.1 log10 and -4.3 log10 copies/mL, respectively. Serum alanine aminotransferase (ALT), albumin, bilirubin, and prothrombin time normalized in 76%, 81%, 50%, and 83% of pre-LT patients and 49%, 76%, 75%, and 20% of post-LT patients. The Child-Pugh-Turcotte (CPT) score improved in over 90% of patients in both cohorts. Genotypic analysis of 122 HBV baseline samples revealed that 98% of these patients had lamivudine-resistant mutant HBV. No adefovir resistance mutations were identified in patients after 48 weeks of therapy. One-year survival was 84% for pre-LT and 93% for post-LT patients (Kaplan-Meier analysis). Treatment-related adverse effects associated with adefovir dipivoxil in this setting were primarily mild to moderate in severity. In conclusion, 48 weeks of adefovir dipivoxil resulted in significant improvements in virologic, biochemical, and clinical parameters in CHB patients pre- and post-LT with lamivudine-resistant HBV.en_HK
dc.languageengen_HK
dc.publisherJohn Wiley & Sons, Inc. The Journal's web site is located at http://www.hepatology.org/en_HK
dc.relation.ispartofHepatologyen_HK
dc.rightsHepatology. Copyright © John Wiley & Sons, Inc.en_HK
dc.subject.meshAdenine - adverse effects - analogs & derivatives - therapeutic useen_HK
dc.subject.meshAdolescenten_HK
dc.subject.meshAdulten_HK
dc.subject.meshAgeden_HK
dc.subject.meshAntiviral Agents - therapeutic useen_HK
dc.subject.meshChilden_HK
dc.subject.meshDrug Resistance, Viralen_HK
dc.subject.meshFemaleen_HK
dc.subject.meshGenotypeen_HK
dc.subject.meshHepatitis B virus - classification - geneticsen_HK
dc.subject.meshHepatitis B, Chronic - drug therapy - virologyen_HK
dc.subject.meshHumansen_HK
dc.subject.meshKidney - drug effectsen_HK
dc.subject.meshLamivudine - therapeutic useen_HK
dc.subject.meshLiver Transplantation - adverse effectsen_HK
dc.subject.meshMaleen_HK
dc.subject.meshMiddle Ageden_HK
dc.subject.meshPhosphonic Acidsen_HK
dc.titleAdefovir Dipivoxil Therapy for Lamivudine-Resistant Hepatitis B in Pre- and Post-Liver Transplantation Patientsen_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=0270-9139&volume=38&spage=1419&epage=1427&date=2003&atitle=Adefovir+Dipivoxil+Therapy+For+Lamivudine-Resistant+Hepatitis+B+In+Pre-+And+Post-Liver+Transplantation+Patientsen_HK
dc.identifier.emailLai, CL:hrmelcl@hku.hken_HK
dc.identifier.authorityLai, CL=rp00314en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.hep.2003.09.040en_HK
dc.identifier.pmid14647053-
dc.identifier.scopuseid_2-s2.0-0344364590en_HK
dc.identifier.hkuros87526en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-0344364590&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume38en_HK
dc.identifier.issue6en_HK
dc.identifier.spage1419en_HK
dc.identifier.epage1427en_HK
dc.identifier.isiWOS:000187032100013-
dc.publisher.placeUnited Statesen_HK
dc.identifier.scopusauthoridSchiff, ER=7102846957en_HK
dc.identifier.scopusauthoridLai, CL=7403086396en_HK
dc.identifier.scopusauthoridHadziyannis, S=35376058400en_HK
dc.identifier.scopusauthoridNeuhaus, P=13702651800en_HK
dc.identifier.scopusauthoridTerrault, N=7003781035en_HK
dc.identifier.scopusauthoridColombo, M=7203013850en_HK
dc.identifier.scopusauthoridTillmann, HL=7006688680en_HK
dc.identifier.scopusauthoridSamuel, D=7102275307en_HK
dc.identifier.scopusauthoridZeuzem, S=7103125178en_HK
dc.identifier.scopusauthoridLilly, L=7006116723en_HK
dc.identifier.scopusauthoridRendina, M=6603675919en_HK
dc.identifier.scopusauthoridVilleneuve, JP=21638015300en_HK
dc.identifier.scopusauthoridLama, N=6602372529en_HK
dc.identifier.scopusauthoridJames, C=7203017674en_HK
dc.identifier.scopusauthoridWulfsohn, MS=6604062041en_HK
dc.identifier.scopusauthoridNamini, H=8871973400en_HK
dc.identifier.scopusauthoridWestland, C=6602914490en_HK
dc.identifier.scopusauthoridXiong, S=7202792127en_HK
dc.identifier.scopusauthoridChoy, GS=36971806400en_HK
dc.identifier.scopusauthoridVan Doren, S=6701612911en_HK
dc.identifier.scopusauthoridFry, J=19134540800en_HK
dc.identifier.scopusauthoridBrosgart, CL=6701704755en_HK

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats